Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Healthcare Disparities | 4 | 2021 | 180 | 0.910 |
Why?
|
| European Continental Ancestry Group | 8 | 2017 | 1076 | 0.820 |
Why?
|
| Colorectal Neoplasms | 4 | 2017 | 219 | 0.750 |
Why?
|
| Adenocarcinoma | 10 | 2016 | 298 | 0.750 |
Why?
|
| African Americans | 8 | 2017 | 1335 | 0.680 |
Why?
|
| Pancreatic Neoplasms | 7 | 2016 | 131 | 0.610 |
Why?
|
| Colonoscopy | 1 | 2017 | 45 | 0.510 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 489 | 0.490 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 461 | 0.490 |
Why?
|
| Minority Health | 1 | 2016 | 5 | 0.480 |
Why?
|
| Transsexualism | 1 | 2016 | 4 | 0.480 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 100 | 0.480 |
Why?
|
| Health Status Disparities | 2 | 2021 | 128 | 0.470 |
Why?
|
| Minority Groups | 1 | 2016 | 81 | 0.460 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 423 | 0.440 |
Why?
|
| Rural Health | 1 | 2014 | 22 | 0.430 |
Why?
|
| Biomedical Research | 1 | 2016 | 178 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 167 | 0.420 |
Why?
|
| Common Bile Duct Neoplasms | 4 | 2016 | 6 | 0.400 |
Why?
|
| Ampulla of Vater | 4 | 2016 | 6 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 108 | 0.400 |
Why?
|
| Middle Aged | 30 | 2021 | 11851 | 0.390 |
Why?
|
| Oxidative Stress | 1 | 2014 | 255 | 0.370 |
Why?
|
| Aged | 25 | 2021 | 10263 | 0.360 |
Why?
|
| Gallbladder Neoplasms | 3 | 2021 | 35 | 0.350 |
Why?
|
| Prostatectomy | 5 | 2020 | 85 | 0.340 |
Why?
|
| Male | 30 | 2021 | 19441 | 0.340 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 28 | 0.340 |
Why?
|
| Appendiceal Neoplasms | 3 | 2017 | 99 | 0.330 |
Why?
|
| Humans | 37 | 2021 | 32282 | 0.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 19 | 0.310 |
Why?
|
| Drug Industry | 1 | 2009 | 16 | 0.310 |
Why?
|
| Female | 25 | 2021 | 19945 | 0.290 |
Why?
|
| Commerce | 1 | 2009 | 69 | 0.290 |
Why?
|
| Biological Products | 1 | 2009 | 79 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 33 | 0.270 |
Why?
|
| Blood Transfusion | 2 | 2017 | 69 | 0.250 |
Why?
|
| Adult | 18 | 2018 | 9259 | 0.250 |
Why?
|
| Mutation | 3 | 2017 | 497 | 0.240 |
Why?
|
| United States | 7 | 2021 | 4072 | 0.240 |
Why?
|
| Radiotherapy | 4 | 2020 | 92 | 0.240 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 13 | 0.230 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.230 |
Why?
|
| Dermatology | 2 | 2018 | 157 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 19 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 180 | 0.220 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 32 | 0.220 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 651 | 0.210 |
Why?
|
| Adenoma | 2 | 2015 | 35 | 0.200 |
Why?
|
| Survival Rate | 9 | 2017 | 893 | 0.200 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 3900 | 0.200 |
Why?
|
| SEER Program | 4 | 2017 | 38 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2240 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 773 | 0.190 |
Why?
|
| Androgen Antagonists | 2 | 2020 | 20 | 0.180 |
Why?
|
| Brachytherapy | 2 | 2020 | 31 | 0.180 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3626 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2021 | 3416 | 0.170 |
Why?
|
| Cytodiagnosis | 2 | 2018 | 15 | 0.170 |
Why?
|
| Bile Ducts | 2 | 2018 | 19 | 0.160 |
Why?
|
| Incidence | 3 | 2017 | 1241 | 0.150 |
Why?
|
| Prognosis | 7 | 2017 | 1534 | 0.150 |
Why?
|
| Registries | 2 | 2017 | 294 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 52 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 222 | 0.140 |
Why?
|
| Marital Status | 2 | 2016 | 21 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 3934 | 0.130 |
Why?
|
| Air Ambulances | 1 | 2017 | 10 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2017 | 30 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2017 | 17 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2017 | 15 | 0.130 |
Why?
|
| Pathology | 1 | 2017 | 20 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.130 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 30 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 556 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 39 | 0.130 |
Why?
|
| Resuscitation | 1 | 2017 | 66 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2017 | 95 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 36 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2017 | 132 | 0.120 |
Why?
|
| Critical Care | 1 | 2017 | 108 | 0.120 |
Why?
|
| Health Priorities | 1 | 2016 | 16 | 0.120 |
Why?
|
| Survivors | 1 | 2017 | 173 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 78 | 0.120 |
Why?
|
| Medicare | 1 | 2017 | 219 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 157 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 83 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 109 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 4 | 0.110 |
Why?
|
| Vitamins | 1 | 2015 | 71 | 0.110 |
Why?
|
| Decision Making | 1 | 2017 | 189 | 0.110 |
Why?
|
| Electrons | 1 | 2015 | 12 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2014 | 1 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 32 | 0.110 |
Why?
|
| Georgia | 1 | 2014 | 15 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2015 | 91 | 0.110 |
Why?
|
| Observer Variation | 3 | 2021 | 96 | 0.110 |
Why?
|
| Isoprostanes | 1 | 2014 | 3 | 0.110 |
Why?
|
| beta Carotene | 1 | 2014 | 6 | 0.110 |
Why?
|
| Africa, Western | 1 | 2014 | 4 | 0.110 |
Why?
|
| Carotenoids | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2014 | 36 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2015 | 113 | 0.110 |
Why?
|
| Age Factors | 5 | 2017 | 1179 | 0.100 |
Why?
|
| Medical Records | 1 | 2014 | 75 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 188 | 0.100 |
Why?
|
| Vitamin D | 1 | 2015 | 186 | 0.100 |
Why?
|
| Social Class | 1 | 2014 | 90 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2020 | 2316 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 194 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 117 | 0.100 |
Why?
|
| Calcium | 1 | 2015 | 339 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 395 | 0.100 |
Why?
|
| Gallbladder | 1 | 2012 | 3 | 0.090 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 2 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 565 | 0.090 |
Why?
|
| Polyps | 1 | 2012 | 9 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 220 | 0.090 |
Why?
|
| Diet | 1 | 2014 | 383 | 0.090 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 545 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 757 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 16 | 0.080 |
Why?
|
| Mucins | 3 | 2016 | 16 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1479 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 754 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 14 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 168 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 2649 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 883 | 0.070 |
Why?
|
| Disease Progression | 3 | 2017 | 591 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 19 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 171 | 0.070 |
Why?
|
| Urinary Incontinence | 2 | 2020 | 68 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2017 | 1840 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 132 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 555 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 324 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 743 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 477 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 5 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 15 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 2205 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1425 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 381 | 0.040 |
Why?
|
| Chile | 1 | 2021 | 7 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 236 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 3519 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 6 | 0.030 |
Why?
|
| Appendectomy | 1 | 2017 | 19 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 30 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 29 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 47 | 0.030 |
Why?
|
| Military Medicine | 1 | 2017 | 26 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2017 | 57 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 59 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2017 | 110 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 81 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 54 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1050 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2017 | 84 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 90 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 287 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 96 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 50 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 146 | 0.030 |
Why?
|
| Urination | 1 | 2016 | 69 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 456 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 315 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 190 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 130 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2015 | 4 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 17 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 91 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 165 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 69 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 11 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 47 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 95 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 305 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 292 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 252 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 359 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 757 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 565 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 216 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 655 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 368 | 0.030 |
Why?
|
| Smoking | 1 | 2017 | 505 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 622 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 232 | 0.020 |
Why?
|
| Mucin-2 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucin-6 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Keratin-7 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 19 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 53 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 65 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 34 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 595 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 964 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 461 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 30 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2435 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 762 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 186 | 0.010 |
Why?
|